Literature DB >> 10026773

Evaluation of asymptomatic microscopic hematuria.

G D Grossfeld1, P R Carroll.   

Abstract

Asymptomatic microscopic hematuria continues to be a common cause for urologic referral. Depending on the population under investigation, the condition is reported in 0.2% to 21.1% of subjects. Many possible etiologies exist for the presence of asymptomatic microscopic hematuria, ranging from insignificant lesions to potentially life-threatening lesions that may require urgent treatment. A cause for asymptomatic microscopic hematuria can be determined in 32% to 100% of patients undergoing a full urologic evaluation, with 3.4% to 56% of these patients having either moderately or highly significant lesions at the time of diagnosis. Consequently, full urologic evaluation is warranted in the majority of patients referred to a urologist with asymptomatic microscopic hematuria. In patients in whom no diagnosis is reached after initial evaluation, follow-up is necessary, although the extent and timing of such follow-up have not been adequately investigated. The ultimate goal of evaluating any patient with asymptomatic microscopic hematuria is the discovery of a significant lesion at an early stage when it is amenable to curative therapy and prior to that lesion causing significant morbidity. No randomized, prospective studies have compared the outcomes of patients with asymptomatic microscopic hematuria undergoing full evaluation with those of patients undergoing surveillance only. The data obtained in high-risk groups undergoing urinary dipstick screening for bladder cancer suggest that the bladder tumors discovered when evaluating all patients with asymptomatic microscopic hematuria may be more amenable to treatment than those normally encountered, thereby possibly reducing the mortality and morbidity associated with bladder cancer in these patients. These findings support the evaluation of patients with asymptomatic microscopic hematuria in a cost-conscious medical environment.

Entities:  

Mesh:

Year:  1998        PMID: 10026773     DOI: 10.1016/s0094-0143(05)70055-0

Source DB:  PubMed          Journal:  Urol Clin North Am        ISSN: 0094-0143            Impact factor:   2.241


  19 in total

1.  Bladder exstrophy-epispadias complex with adenocarcinoma in an adult patient: A case report.

Authors:  Wei Xiong; Ran Peng; Liang Zhu; Zhaohui Zhong
Journal:  Exp Ther Med       Date:  2015-10-13       Impact factor: 2.447

2.  Invasive Squamous Carcinoma and Adenocarcinoma of an Unreconstructed Exstrophic Bladder with HPV Infection.

Authors:  Mesut Altan; Burak Çıtamak; Hakan Bahadır Haberal; Emrullah Söğütdelen; Ali Cansu Bozaci; Dilek Ertoy Baydar; Hasan Serkan Doğan; Serdar Tekgül
Journal:  Curr Urol       Date:  2016-05-20

3.  Evaluation of urinary XIAP as a diagnostic biomarker of carcinoma of urinary bladder.

Authors:  A K Srivastava; P K Singh; D Singh; D Dalela; S K Rath; M M Goel; M L B Bhatt
Journal:  Tumour Biol       Date:  2014-05-23

4.  Appraisal of diagnostic ability of UCA1 as a biomarker of carcinoma of the urinary bladder.

Authors:  A K Srivastava; P K Singh; S K Rath; D Dalela; M M Goel; M L B Bhatt
Journal:  Tumour Biol       Date:  2014-08-15

5.  Using urine microscopy and cytology for early detection of bladder cancer in male patients with lower urinary tract symptoms.

Authors:  Eddie S Y Chan; Chi-Fai Ng; See-Ming Hou; Sidney K H Yip
Journal:  Int Urol Nephrol       Date:  2010-11-04       Impact factor: 2.370

6.  Bladder wall thickness mapping for magnetic resonance cystography.

Authors:  Yang Zhao; Zhengrong Liang; Hongbin Zhu; Hao Han; Chaijie Duan; Zengmin Yan; Hongbing Lu; Xianfeng Gu
Journal:  Phys Med Biol       Date:  2013-07-09       Impact factor: 3.609

7.  [Methods and current significance of the evaluation of microscopic haematuria].

Authors:  P Hüppe; F Wawroschek
Journal:  Urologe A       Date:  2011-03       Impact factor: 0.639

8.  A male presenting with a primary mucinous bladder carcinoma: a case report.

Authors:  Konstantinos Sigalas; Stavros I Tyritzis; Eleni Trigka; Ioannis Katafigiotis; Nikolaos Kavantzas; Konstantinos G Stravodimos
Journal:  Cases J       Date:  2010-02-03

Review 9.  Bladder tumor markers: from hematuria to molecular diagnostics--where do we stand?

Authors:  Samir P Shirodkar; Vinata B Lokeshwar
Journal:  Expert Rev Anticancer Ther       Date:  2008-07       Impact factor: 4.512

10.  CEUS in the differentiation between low and high-grade bladder carcinoma.

Authors:  F M Drudi; N Di Leo; F Malpassini; F Antonini; E Corongiu; F Iori
Journal:  J Ultrasound       Date:  2012-09-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.